ISBN: Study Applicability Limitations Other comments Costs Effects Inc. cost Inc. effects Cost- effectiveness Uncertainty modelled Pufulete (Mohiud ) [UK] Directly applicable(e) Minor Limitations (f) Cost-utility analysis, Markov model Comparators: clinically-guided therapy 2. Specialist-led BNP- guided therapy Lifetime horizon modelled Population split into multiple sub-groups: o All HF patients aged - - 2-1: QALY gained Probability cost- o HF-REF patients aged <75 years - - 2-1: QALY gained Probability cost- threshold): NR o HF-PEF patients aged <75 years - - 2-1: QALY gained Probability cost- o All HF patients 75 years - - 2-1: saves (less costly, more effective) Probability cost- threshold): NR o HF-REF patients 75 years - - 2-1: QALY gained Probability cost- Abbreviations: BNP: brain natriuretic peptide; CHF: chronic heart failure; ICER: incremental cost-effectiveness ratio; HF; heart failure; LVSD; left ventricular systolic dysfunction; MDT: multidisciplinary team; QALY: quality-adjusted life years; RCT: randomised controlled trial Monitoring Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: (a) Preference weights of EQ-5D scores were based on subjects region of origin, not necessarily UK tariff (31% US, 52% Western Europe, 14% Latin America). Disease progression not captured in the model. (b) Austrian payer perspective. EQ-5D not used to capture quality of life - utility scores converted from MLWHF questionnaire using previously published algorithm. Costs and effects discounted at 5%. (c) Cost of GP visits and drug costs were not collected and not included in the analysis of the clinical trial phase. (d) None (e) Disease progression not captured in the model. Chronic Heart Failure Monitoring NICE 2018. All rights reserved. Subject to Notice of rights. 